Wutah dodolan YoY sajrone 12 wulan kepungkur: Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals (CRVS) is deploying capital toward testing without current revenues, anticipating breakthrough results for socrelitinib. The GURU.Markets platform displays the relative sales growth over a 12-month period compared to last year, where the value 0.00 represents the current metric. Leading oncologists, drawn by the opportunity to implement cutting-edge scientific research in the fight against lymphomas, drive the company's success.
Ringkesan rincian data analitis Corvus Pharma (CRVS)

This metric measures the percentage change in revenue over a rolling twelve-month period, allowing for an assessment of the actual speed of the business's commercial expansion and the pace of its market share scaling. For Corvus Pharmaceuticals (CRVS), which develops monopoly cancer immunotherapy tools, the year-over-year sales dynamics for the last 12 months TTM on the GURU.Markets platform serve as an indicator of the commercialization efficiency of patented drugs following FDA approval.